Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Reich, O; Liegl, B; Tamussino, K; Regauer, S.
p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease.
Mod Pathol. 2005; 18(3):354-357
Doi: 10.1038/modpathol.3800243
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Reich Olaf
- Co-Autor*innen der Med Uni Graz
- Liegl-Atzwanger Bernadette
- Regauer Sigrid
- Tamussino Karl
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- We evaluated p186Her2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease. We identified six patients with recurrent vulvar Paget's disease in our archives. The number of recurrences ranged from 1 to 11 over a time period of 1-168 months. Recurrences were evaluated immunohistochemically for p185Her2 overexpression with the HercepTest and for HER2 oncogene amplification with fluorescence in situ hybridization. p185Her2 overexpression was scored as 3 in two patients, as 2 in two patients, and as 1 in two patients. All patients with scores 2 and 3 showed HER2 oncogene amplification. Overexpression of p185Her2 and HER2 oncogene amplification appears to be common in recurrent vulvar Paget's disease.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Female -
- Gene Amplification -
- Humans -
- Immunohistochemistry -
- In Situ Hybridization, Fluorescence -
- Middle Aged -
- Neoplasm Recurrence, Local -
- Paget's Disease, Extramammary - genetics
- Receptor, erbB-2 - biosynthesis
- Vulvar Neoplasms - genetics
- Find related publications in this database (Keywords)
- Paget's disease
- p185
- HER2
- vulva
- treatment
- trastuzumab
- immunotherapy